<?xml version="1.0" encoding="UTF-8"?>
<?xml-stylesheet href="/rss.css" type="text/css"?>
<rdf:RDF xmlns="http://purl.org/rss/1.0/"
    xmlns:cc="http://web.resource.org/cc/"
    xmlns:dc="http://purl.org/dc/elements/1.1/"
    xmlns:extra="http://www.w3.org/1999/xhtml"
    xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/"
    xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#">
    <channel rdf:about="http://www.biomedcentral.com/feeds/latestarticles/journal?journal=bmcwomenshealth&amp;quantity=&amp;format=rss&amp;version=">
        <title>BMC Women&apos;s Health - Latest Articles</title>
        <link>http://www.biomedcentral.com/bmcwomenshealth/</link>
        <description>The latest research articles published by BMC Women&apos;s Health</description>
        <dc:date>2012-05-28T00:00:00Z</dc:date>
        <items>
            <rdf:Seq>
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1472-6874/12/14" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1472-6874/12/13" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1472-6874/12/12" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1472-6874/12/11" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1472-6874/12/10" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1472-6874/12/9" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1472-6874/12/8" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1472-6874/12/7" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1472-6874/12/6" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1472-6874/12/5" />
                            </rdf:Seq>
        </items>
                 <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </channel>
        <item rdf:about="http://www.biomedcentral.com/1472-6874/12/14">
        <title>Receiving voluntary family planning services has no relationship with the paradoxical situation of high use of contraceptives and abortion in Viet Nam: a cross sectional study</title>
        <description>Background and objectivesViet Nam shows a paradoxical situation where high contraceptive prevalence goes together with high abortion rates. This study examined the associations between self-reports of having received voluntary family planning (VFP) services and induced abortions.
Methods:
A cross sectional survey was conducted in Thai Nguyen province, covering a total of 1281 women. Data were derived from a sample of 935 married women aged 18-49 years who were ever-users (93.5 percent) and current users of contraceptives (84 percent), and had completed birth histories. The dependent variables were the likelihood of having an induced abortion and repeated (two or more) induced abortions. The main independent variable was having received the three VFP dimensions (counselling, broader information, and access to availability). The association was examined using multivariate logistic regressions, taking into account women&apos;s socio-demographic characteristics.
Results:
The overall induced abortion percentage was 19.4 per 100 pregnancies. None of the three VFP dimensions was significantly associated with the odds of having an induced abortion or having repeated induced abortions. Mother&apos;s age of 35 or older, having more than three living children, and ever used female contraception methods significantly doubled or more the odds of having an induced abortion and significantly tripled the odds of having repeated abortions.
Conclusions:
Results indicate that women receiving VFP services were not less likely to have induced abortions. The provision of family planning counselling, information on contraceptive method mix, and management skills to ensure availability, are in need of reinforcement in a new set of policy and program strategies in the future.</description>
        <link>http://www.biomedcentral.com/1472-6874/12/14</link>
                <dc:creator>Phuong Nguyen</dc:creator>
                <dc:creator>Meiwita Budiharsana</dc:creator>
                <dc:source>BMC Women&apos;s Health 2012, null:14</dc:source>
        <dc:date>2012-05-28T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1472-6874-12-14</dc:identifier>
                                <prism:require>/content/figures/1472-6874-12-14-toc.gif</prism:require>
                <prism:publicationName>BMC Women&apos;s Health</prism:publicationName>
        <prism:issn>1472-6874</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>14</prism:startingPage>
        <prism:publicationDate>2012-05-28T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1472-6874/12/13">
        <title>Barriers to condom use among women at risk of HIV/AIDS: a qualitative study from Iran</title>
        <description>Background:
The growing trend of women infected with HIV through sexual transmission is alarming. Factors influencing condom use have not yet been fully identified, especially in countries with conservative cultures and backgrounds. The present study aimed to explore the barriers of condom use in Iranian women at risk of HIV.
Methods:
Using the grounded theory methodology, participants&apos; experiences and their perceptions regarding condom were collected during semi structured in depth interviews. Participants were 22 women, aged 21-49 years, considered to be at risk for HIV, due to their own or their partner&apos;s sexual behaviors. Qualitative analysis of the data was conducted manually and was guided by constant comparative analysis.
Results:
Two main barriers, personal and socio-environmental emerged from data  analysis. Lack of perceived threat, absence of protective motivation, inadequate knowledge, perceived lack of control, negative attitudes towards condom and misperception were the major personal barriers, while unsupportive environments and cultural norms were the  common socioenvironmental barriers to condom use among these at risk women.
Conclusions:
These critical barriers have to be addressed for implementing effective prevention programs against HIV among populations at risk for HIV.</description>
        <link>http://www.biomedcentral.com/1472-6874/12/13</link>
                <dc:creator>Razieh Lotfi</dc:creator>
                <dc:creator>Fahimeh Ramezani Tehrani</dc:creator>
                <dc:creator>Farideh Yaghmaei</dc:creator>
                <dc:creator>Ebrahim Hajizadeh</dc:creator>
                <dc:source>BMC Women&apos;s Health 2012, null:13</dc:source>
        <dc:date>2012-05-24T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1472-6874-12-13</dc:identifier>
                                <prism:require>/content/figures/1472-6874-12-13-toc.gif</prism:require>
                <prism:publicationName>BMC Women&apos;s Health</prism:publicationName>
        <prism:issn>1472-6874</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>13</prism:startingPage>
        <prism:publicationDate>2012-05-24T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1472-6874/12/12">
        <title>DNA-testing for BRCA1/2 prior to genetic counseling in patients with breast cancer: Design of an intervention study, DNA-direct</title>
        <description>Background:
Current practice for patients with breast cancer referred for genetic counseling, includes face-to-face consultations with a genetic counselor prior to and following DNATestingThis is based on guidelines regarding Huntington&apos;s disease in anticipation of high psychosocial impact of DNA-testing for mutations in BRCA1/2 genes. The initial consultation covers generic information regarding hereditary breast cancer and the (im)possibilities of DNA-testing, prior to such testing. Patients with breast cancer may see this information as irrelevant or unnecessary because individual genetic advice depends on DNA-test results. Also, verbal information is not always remembered well by patients. A different format for this information prior to DNA-testing is possible: replacing initial face-to-face genetic counseling (DNA-intake procedure) by telephone, written and digital information sent to patients&apos; homes (DNA-direct procedure).
Methods:
In this intervention study, 150 patients with breast cancer referred to the department of Clinical Genetics of the Radboud University Nijmegen Medical Centre are given the choice between two procedures, DNA-direct (intervention group) or DNA-intake (usual care, control group). During a triage telephone call, patients are excluded if they have problems with Dutch text, family communication, or of psychological or psychiatric nature. Primary outcome measures are satisfaction and psychological distress. Secondary outcome measures are determinants for the participant&apos;s choice of procedure, waiting and processing times, and family characteristics. Data are collected by self-report questionnaires at baseline and following completion of genetic counseling. A minority of participants will receive an invitation for a 30 minute semi-structured telephone interview, e.g. confirmed carriers of a BRCA1/2 mutation, and those who report problems with the procedure.DiscussionThis study compares current practice of an intake consultation (DNA-intake) to a home informational package of telephone, written and digital information (DNA-direct) prior to DNA-testing in patients with breast cancer. The aim is to determine whether DNA-direct is an acceptable procedure for BRCA1/2 testing, in order to provide customized care to patients with breast cancer, cutting down on the period of uncertainty during this diagnostic process.Trial registration: The study is registered at the Dutch Trial Registry www.trialregister.nl (NTR3018).</description>
        <link>http://www.biomedcentral.com/1472-6874/12/12</link>
                <dc:creator>Aisha Sie</dc:creator>
                <dc:creator>Liesbeth Spruijt</dc:creator>
                <dc:creator>Wendy van Zelst-Stams</dc:creator>
                <dc:creator>Arjen Mensenkamp</dc:creator>
                <dc:creator>Marjolijn Ligtenberg</dc:creator>
                <dc:creator>Han Brunner</dc:creator>
                <dc:creator>Judith Prins</dc:creator>
                <dc:creator>Nicoline Hoogerbrugge</dc:creator>
                <dc:source>BMC Women&apos;s Health 2012, null:12</dc:source>
        <dc:date>2012-05-08T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1472-6874-12-12</dc:identifier>
                                <prism:require>/content/figures/1472-6874-12-12-toc.gif</prism:require>
                <prism:publicationName>BMC Women&apos;s Health</prism:publicationName>
        <prism:issn>1472-6874</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>12</prism:startingPage>
        <prism:publicationDate>2012-05-08T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1472-6874/12/11">
        <title>Hypovitaminosis D and prevalent asymptomatic vertebral fractures in Moroccan postmenopausal women.</title>
        <description>Objectiveto determine serum vitamin D status and to assess the association of vitamin D status with bone mineral density (BMD) and asymptomatic vertebral fractures (VFs) prevalence using vertebral fracture assessment (VFA) in a cohort of Moroccan menopausal women.Materials and methods: from june to september 2010, 178 menopausal women 50 years old and over were enrolled in this cross-sectional study. The mean +/- SD (range) age, weight and BMI were 58.8+/- 8.2 (50 to 79) years, 73.2+/- 13.8 (35 to 119) Kgs and 29.8+/- 5.9 (17.5 - 49.8) kg/m2, respectively. VFA images and scans of the lumbar spine and proximal femur were obtained using a GE Healthcare Lunar Prodigy densitometer. VFs were defined using a combination of Genant semiquantitative approach and morphometry. Serum levels of 25-hydroxyvitamin D (25(OH)D) were measured.
Results:
Among the 178 women, 45 (25.2%) had densitometric osteoporosis, and on VFA, VFs (grade 2 or 3) were detected in 20.2% while grade 1 were identified in 33.1%. The mean values of serum levels of 25(OH)D were 15.8+/- 11.6 ng/ml (range: 3.0 - 49.1) with 152 patients (85.3%) having levels &lt;30ng/ml (insufficiency) and 92 (51.6%) &lt;10ng/ml (deficiency). Stepwise regression analysis showed that presence of VFs was independently related to age, 25(OH)D and densitometric osteoporosis.
Conclusion:
our study shows that advanced age, hypovitaminosis D and osteoporosis are independent risk factors for asymptomatic VFs in Moroccan postmenopausal women.</description>
        <link>http://www.biomedcentral.com/1472-6874/12/11</link>
                <dc:creator>Abdellah El Maghraoui</dc:creator>
                <dc:creator>Zhor Ouzzif</dc:creator>
                <dc:creator>Aziza Mounach</dc:creator>
                <dc:creator>Asmaa Rezqi</dc:creator>
                <dc:creator>Lahsen Achemlal</dc:creator>
                <dc:creator>Ahmed Bezza</dc:creator>
                <dc:creator>Saida Tella</dc:creator>
                <dc:creator>Mohamed Dehhaoui</dc:creator>
                <dc:creator>Imad Ghozlani</dc:creator>
                <dc:source>BMC Women&apos;s Health 2012, null:11</dc:source>
        <dc:date>2012-04-24T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1472-6874-12-11</dc:identifier>
                                <prism:require>/content/figures/1472-6874-12-11-toc.gif</prism:require>
                <prism:publicationName>BMC Women&apos;s Health</prism:publicationName>
        <prism:issn>1472-6874</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>11</prism:startingPage>
        <prism:publicationDate>2012-04-24T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1472-6874/12/10">
        <title>Assessment of leukemia inhibitory factor and glycoprotein 130 expression in endometrium and uterine flushing: a possible diagnostic tool for impaired fertility
 
</title>
        <description>Background:
Uterine receptivity and implantation are complex processes requiring coordinated expression of molecules by zygote and uterus. Our objective was to evaluate the role of the endometrial expression of leukemia inhibitory factor (LIF) and its glycoprotein 130 (gp130) receptor molecules and their secretion in uterine flushing during the window of implantation in cases of primary unexplained infertilityCase presentationThe study was conducted on 25 infertile women with unexplained infertility for at least two years and 10 normal fertile women as a control group . Endometrial tissue and uterine flushing were obtained. Each tissue specimen was divided into two pieces; one piece was used for histological dating of the endometrium and for immunostaining of progesterone receptors, and the second was used for RNA extraction and PCR assay of LIF and gp130 mRNA expression. Serum estrogen and progesterone were measured for all subjects. LIF mRNA was expressed in the endometrium of all normal fertile women but significantly decreased in infertile women. LIF was not detectable in 88% of infertile women while it was fairly detectable in 12% of them. Gp130 mRNA was hardly detectable in both fertile and infertile women with no difference between them. Infertile women secreted significantly less LIF and gp130 molecules in the uterine flushing compared with normal fertile women. \
Conclusions:
Expression of LIF mRNA in endometrium could be used as a molecular marker of unexplained infertility. Assessment of secreted LIF and gp130 molecules in uterine flushing could be another useful and safe method for predicting successful implantation as well as for diagnosing and eventually treating women with impaired fertility using recombinant human LIF.</description>
        <link>http://www.biomedcentral.com/1472-6874/12/10</link>
                <dc:creator>Manal Hammoda</dc:creator>
                <dc:creator>Manal Eid</dc:creator>
                <dc:creator>Hesham El-Srogy</dc:creator>
                <dc:creator>Manal Mostafa</dc:creator>
                <dc:creator>Azza Hasan</dc:creator>
                <dc:source>BMC Women&apos;s Health 2012, null:10</dc:source>
        <dc:date>2012-04-20T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1472-6874-12-10</dc:identifier>
                            <dc:title>Potential markers for unexplained infertility</dc:title>
                            <dc:description>Endometrial tissue from women with unexplained infertility contains significantly lower levels of LIF (leukemia inhibitory factor) mRNA compared to tissue from normally fertile women, suggesting that LIF could be used as a biomarker for infertility.</dc:description>
                <prism:require>/content/figures/1472-6874-12-10-toc.gif</prism:require>
                <prism:publicationName>BMC Women&apos;s Health</prism:publicationName>
        <prism:issn>1472-6874</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>10</prism:startingPage>
        <prism:publicationDate>2012-04-20T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1472-6874/12/9">
        <title>Treatment of endometriosis in different ethnic populations: a meta-analysis of two clinical trials</title>
        <description>Approaches to the treatment of endometriosis vary worldwide, but studies comparing endometriosis medications in different ethnic groups are rare. A systematic literature search identified two studies directly comparing dienogest (DNG) versus gonadotropin-releasing hormone (GnRH) analogues in European and Japanese populations. Meta-analysis of visual analogue scale scores revealed no heterogeneity in response between the trials, indicating equivalent efficacy of DNG and GnRH analogues for endometriosis-related pain across populations. DNG was significantly superior to GnRH analogues for bone mineral density change in both trials, but significant heterogeneity between the studies may indicate ethnic differences in physiology.</description>
        <link>http://www.biomedcentral.com/1472-6874/12/9</link>
                <dc:creator>Christoph Gerlinger</dc:creator>
                <dc:creator>Thomas Faustmann</dc:creator>
                <dc:creator>Jeffrey Hassal</dc:creator>
                <dc:creator>Christian Seitz</dc:creator>
                <dc:source>BMC Women&apos;s Health 2012, null:9</dc:source>
        <dc:date>2012-04-19T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1472-6874-12-9</dc:identifier>
                            <dc:title>Endometriosis treatment unaffected by ethnicity</dc:title>
                            <dc:description>Dienogest (DNG) and gonadotropin-releasing hormone (GnRH) analogues are effective in treating endometriosis-related pain in both Japanese and European populations, suggesting that medication for endometriosis is not affected by ethnic differences in physiology.</dc:description>
                <prism:require>/content/figures/1472-6874-12-9-toc.gif</prism:require>
                <prism:publicationName>BMC Women&apos;s Health</prism:publicationName>
        <prism:issn>1472-6874</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>9</prism:startingPage>
        <prism:publicationDate>2012-04-19T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1472-6874/12/8">
        <title>Rates of IUCD discontinuation and its associated factors among the clients of a social franchising network in Pakistan</title>
        <description>Background:
Modern Intrauterine contraceptive device (IUCD) is very safe, highly effective reversible and inexpensive family planning method which offers 5-10 years of protection against pregnancy. The contraceptive use in Pakistan has been merely 30% for over a decade with IUCD being the least used method. Higher discontinuation rates are documented in developing countries; however no such data is available for Pakistan. Marie Stopes Society (MSS) established a social franchise outlets network branded as &apos;SURAJ&apos; (Sun) in Pakistan to provide quality family planning services. This study attempts to determine IUCD discontinuation rates and its associated risk factors. Using a semi-structured questionnaire, a cross-sectional study was conducted with 3000 clients who availed IUCD services from Suraj provider 6, 12 and 24 month back,. Data were analyzed in SPSS 17.0; adjusted prevalence ratios were calculated to see associations between discontinuation and its risk factors.Case presentationWe found that 22.7% of the IUCD acceptors experienced some health problem; while the overall discontinuation rate was 18.9% with average time of usage of 7.4 (SD &#177; 5.8) months before discontinuation. Half of them showed health concerns (49.8%); of which a majority (70.2%) returned to Suraj provider for IUCD removal. Women living in Punjab, residing at a travelling time of 30-60 minutes and no previous use of contraceptive are more likely to discontinue IUCD. However, among total women 81.7% still expressed willingness to avail IUCD services from Suraj provider in future, if needed.
Conclusion:
The findings suggest a need for training the providers and field workers to prevent early discontinuation of IUCD among the Suraj clients and by addressing the health concerns through proper counseling, continued follow-up and immediate medical aid/referral in case of complications.</description>
        <link>http://www.biomedcentral.com/1472-6874/12/8</link>
                <dc:creator>Khurram Azmat</dc:creator>
                <dc:creator>Babar Shaikh</dc:creator>
                <dc:creator>Waqas Hameed</dc:creator>
                <dc:creator>Mohsina Bilgrami</dc:creator>
                <dc:creator>Ghulam Mustafa</dc:creator>
                <dc:creator>Muhammad Ali</dc:creator>
                <dc:creator>Wajahat Hussain</dc:creator>
                <dc:creator>Aftab Ahmad</dc:creator>
                <dc:creator>Muhammad Ishaque</dc:creator>
                <dc:source>BMC Women&apos;s Health 2012, null:8</dc:source>
        <dc:date>2012-03-29T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1472-6874-12-8</dc:identifier>
                                <prism:require>/content/figures/1472-6874-12-8-toc.gif</prism:require>
                <prism:publicationName>BMC Women&apos;s Health</prism:publicationName>
        <prism:issn>1472-6874</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>8</prism:startingPage>
        <prism:publicationDate>2012-03-29T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1472-6874/12/7">
        <title>Socioeconomic conditions and number of pain sites in women</title>
        <description>Background:
Women in deprived socioeconomic situations run a high pain risk. Although number of pain sites (NPS) is considered highly relevant in pain assessment, little is known regarding the relationship between socioeconomic conditions and NPS.
Methods:
The study population comprised 653 women; 160 recurrence-free long-term gynecological cancer survivors, and 493 women selected at random from the general population. Demographic characteristics and co-morbidity over the past 12 months were assessed. Socioeconomic conditions were measured by Socioeconomic Condition Index (SCI), comprising education, employment status, income, ability to pay bills, self-perceived health, and satisfaction with number of close friends. Main outcome measure NPS was recorded using a body outline diagram indicating where the respondents had experienced pain during the past week. Chi-square test and forward stepwise logistic regression were applied.Results and ConclusionThere were only minor differences in SCI scores between women with 0, 1-2 or 3 NPS. Four or more NPS was associated with younger age, higher BMI and low SCI. After adjustment for age, BMI and co-morbidity, we found a strong association between low SCI scores and four or more NPS, indicating that there is a threshold in the NPS count for when socioeconomic determinants are associated to NPS in women.</description>
        <link>http://www.biomedcentral.com/1472-6874/12/7</link>
                <dc:creator>Finn Skjeldestad</dc:creator>
                <dc:creator>Toril Rannestad</dc:creator>
                <dc:source>BMC Women&apos;s Health 2012, null:7</dc:source>
        <dc:date>2012-03-29T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1472-6874-12-7</dc:identifier>
                                <prism:require>/content/figures/1472-6874-12-7-toc.gif</prism:require>
                <prism:publicationName>BMC Women&apos;s Health</prism:publicationName>
        <prism:issn>1472-6874</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>7</prism:startingPage>
        <prism:publicationDate>2012-03-29T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1472-6874/12/6">
        <title>Prevalence, symptoms and management of uterine fibroids: an international internet-based survey of 21,746 women</title>
        <description>Background:
In 2009 the Uterine Bleeding and Pain Women&apos;s Research Study (UBP-WRS) was conducted interviewing 21,479 women across 8 countries in order to gain patient-based prevalence data on uterine pain and bleeding indications and investigate uterine symptoms and women&apos;s treatment experiences. This article shows relevant results of the study for the indication uterine fibroids providing data on self-reported prevalence, symptomatology and management of uterine fibroids.
Methods:
2,500 women (USA: 4,500 women) in each country (Brazil, Canada, France, Germany, Italy, South Korea, the UK, the USA) completed an online survey. Women included were in their reproductive age (age group 15-49 years; USA: 18-49 years) and had ever experienced menstrual bleedings. Quotas were applied for age, region, level of education and household income of respondents. Variables have been analyzed descriptively and exploratory statistical tests have been performed.
Results:
The self-reported prevalence of uterine fibroids ranged from 4.5% (UK) to 9.8% (Italy), reaching 9.4% (UK) to 17.8% (Italy) in the age group of 40-49 years. Women with a diagnosis of uterine fibroids reported significantly more often about bleeding symptoms than women without a diagnosis: heavy bleedings (59.8% vs. 37.4%), prolonged bleedings (37.3% vs. 15.6%), bleeding between periods (33.3% vs. 13.5%), frequent periods (28.4% vs. 15.2%), irregular and predictable periods (36.3% vs. 23.9%). Furthermore women with diagnosed uterine fibroids reported significantly more often about the following pain symptoms: pressure on the bladder (32.6% vs. 15.0%), chronic pelvic pain (14.5% vs. 2.9%), painful sexual intercourse (23.5% vs. 9.1%) and pain occurring mid-cycle, after and during menstrual bleeding (31.3%, 16.7%, 59.7%, vs. 17.1%, 6.4%, 52.0%). 53.7% of women reported that their symptoms had a negative impact on their life in the last 12 month, influencing their sexual life (42.9%), performance at work (27.7%) and relationship &amp; family (27.2%).
Conclusions:
Uterine fibroid is a common concern in women at fertile age causing multiple bleeding and pain symptoms which can have a negative impact on different aspects in women&apos;s life.</description>
        <link>http://www.biomedcentral.com/1472-6874/12/6</link>
                <dc:creator>Anne Zimmermann</dc:creator>
                <dc:creator>David Bernuit</dc:creator>
                <dc:creator>Christoph Gerlinger</dc:creator>
                <dc:creator>Matthias Schaefers</dc:creator>
                <dc:creator>Katharina Geppert</dc:creator>
                <dc:source>BMC Women&apos;s Health 2012, null:6</dc:source>
        <dc:date>2012-03-26T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1472-6874-12-6</dc:identifier>
                            <dc:title>The global impact of uterine fibroids</dc:title>
                            <dc:description>Uterine fibroids occur in a significant proportion of women of reproductive age worldwide, and frequently result in symptoms including bleeding and pain, suggesting that the negative impact of uterine fibroids is a global phenomenon.</dc:description>
                <prism:require>/content/figures/1472-6874-12-6-toc.gif</prism:require>
                <prism:publicationName>BMC Women&apos;s Health</prism:publicationName>
        <prism:issn>1472-6874</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>6</prism:startingPage>
        <prism:publicationDate>2012-03-26T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1472-6874/12/5">
        <title>Non-inferiority of short-term urethral catheterization following fistula repair surgery: study protocol for a randomized controlled trial</title>
        <description>Background:
A vaginal fistula is a devastating condition, affecting an estimated 2 million girls and women across Africa and Asia. There are numerous challenges associated with providing fistula repair services in developing countries, including limited availability of operating rooms, equipment, surgeons with specialized skills, and funding from local or international donors to support surgeries and subsequent post-operative care. Finding ways of providing services in a more efficient and cost-effective manner, without compromising surgical outcomes and the overall health of the patient, is paramount. Shortening the duration of urethral catheterization following fistula repair surgery would increase treatment capacity, lower costs of services, and potentially lower risk of healthcare-associated infections among fistula patients. There is a lack of empirical evidence supporting any particular length of time for urethral catheterization following fistula repair surgery. This study will examine whether short-term (7 day) urethral catheterization is not worse by more than a minimal relevant difference to longer-term (14 day) urethral catheterization in terms of incidence of fistula repair breakdown among women with simple fistula presenting at study sites for fistula repair service.Methods/DesignThis study is a facility-based, multicenter, non-inferiority randomized controlled trial (RCT) comparing the new proposed short-term (7 day) urethral catheterization to longer-term (14 day) urethral catheterization in terms of predicting fistula repair breakdown. The primary outcome is fistula repair breakdown up to three months following fistula repair surgery as assessed by a urinary dye test. Secondary outcomes will include repair breakdown one week following catheter removal, intermittent catheterization due to urinary retention and the occurrence of septic or febrile episodes, prolonged hospitalization for medical reasons, catheter blockage, and self-reported residual incontinence. This trial will be conducted among 512 women with simple fistula presenting at 8 study sites for fistula repair surgery over the course of 24 months at each site.DiscussionIf no major safety issues are identified, the data from this trial may facilitate adoption of short-term urethral catheterization following repair of simple fistula in sub-Saharan Africa and Asia.Trial registrationClinicalTrials.gov Identifier NCT01428830.</description>
        <link>http://www.biomedcentral.com/1472-6874/12/5</link>
                <dc:creator>Mark Barone</dc:creator>
                <dc:creator>Vera Frajzyngier</dc:creator>
                <dc:creator>Steven Arrowsmith</dc:creator>
                <dc:creator>Joseph Ruminjo</dc:creator>
                <dc:creator>Armando Seuc</dc:creator>
                <dc:creator>Evelyn Landry</dc:creator>
                <dc:creator>Karen Beattie</dc:creator>
                <dc:creator>Thierno Hamidou Barry</dc:creator>
                <dc:creator>Alyona Lewis</dc:creator>
                <dc:creator>Mulu Muleta</dc:creator>
                <dc:creator>Dolores Nembunzu</dc:creator>
                <dc:creator>Robert Olupot</dc:creator>
                <dc:creator>Ileogben Sunday-Adeoye</dc:creator>
                <dc:creator>Weston Khisa Wakasiaka</dc:creator>
                <dc:creator>Mariana Widmer</dc:creator>
                <dc:creator>A. Metin Gulmezoglu</dc:creator>
                <dc:source>BMC Women&apos;s Health 2012, null:5</dc:source>
        <dc:date>2012-03-20T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1472-6874-12-5</dc:identifier>
                                <prism:require>/content/figures/1472-6874-12-5-toc.gif</prism:require>
                <prism:publicationName>BMC Women&apos;s Health</prism:publicationName>
        <prism:issn>1472-6874</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>5</prism:startingPage>
        <prism:publicationDate>2012-03-20T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <cc:License rdf:about="http://creativecommons.org/licenses/by/2.0/">
        <cc:permits rdf:resource="http://creativecommons.org/ns#Reproduction" />
        <cc:permits rdf:resource="http://creativecommons.org/ns#Distribution" />
        <cc:permits rdf:resource="http://creativecommons.org/ns#DerivativeWorks" />
    </cc:License>
</rdf:RDF>

